Lauren Eschmann
Family · Americus, GANPI 1316475734
Payments from drug & device makers
Across 169 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Novo Nordisk$697
- AstraZeneca$253
- AbbVie$130
- Astellas Pharma US Inc$95
- Lilly USA, LLC$77
- plus $414 from 13 others
What the payments were for
- Food & beverage$2,63397%
- Education$953%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $1,061 |
| Novo Nordisk | 54 | $697 |
| AstraZeneca | 14 | $253 |
| AbbVie | 7 | $130 |
| Astellas Pharma US Inc | 1 | $95 |
| Lilly USA, LLC | 4 | $77 |
| Boehringer Ingelheim | 4 | $74 |
| Amgen | 4 | $58 |
| Exact Sciences | 3 | $51 |
| Pfizer | 2 | $33 |
| Merck | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Ardelyx, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 2 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
How this compares
$2,728 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $96,699 |
| JardianceEmpagliflozin | 54 | $62,734 |
| JanuviaSitagliptin Phosphate | 51 | $52,713 |
| TrulicityDulaglutide | 24 | $43,948 |
| MounjaroTirzepatide | 36 | $39,060 |
| TradjentaLinagliptin | 38 | $36,209 |
| RybelsusSemaglutide | 12 | $25,486 |
| LinzessLinaclotide | 24 | $24,809 |
| XareltoRivaroxaban | 16 | $21,256 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $18,204 |
| FarxigaDapagliflozin Propanediol | 22 | $17,305 |
| VraylarCariprazine Hcl | 11 | $15,213 |
| EntrestoSacubitril/Valsartan | 11 | $12,390 |
| MyrbetriqMirabegron | 13 | $11,997 |
| EliquisApixaban | 12 | $11,539 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $697 | $122,18588 claims |
| Boehringer IngelheimJardiance, Tradjenta | $74 | $98,94392 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $77 | $83,00860 claims |
| MerckJanuvia | $31 | $52,71351 claims |
| AbbVieLinzess, Vraylar | $130 | $40,02235 claims |
| AstraZenecaFarxiga, Symbicort | $253 | $23,34544 claims |
| GSKTrelegy Ellipta | $1,061 | $18,20422 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $11,99713 claims |
| PfizerEliquis | $33 | $11,53912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.
Other family in Americus
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.